sparsentan · Filspari

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: IgA Nephropathy, Focal Segmental Glomerulosclerosis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (1)
EU
  • Filspari is indicated for the treatment of adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion > 1.0 g/day (or urine protein-to-creatinine ratio > 0.75 g/g, see section 5.1).
Product first approved 2024EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Focal Segmental Glomerulosclerosis
IgA Nephropathy
Phase 2 (5)
Focal Segmental Glomerulosclerosis
NCT05003986 · Travere Therapeutics, Inc.
2021-08-12 – 2027-04-12 · Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis, Alport Syndrome
What this study did
NCT01613118 · Travere Therapeutics, Inc.
2014-03 – 2024-03-25 · Focal Segmental Glomerulosclerosis
What this study did
IgA Nephropathy
NCT04663204 · University of Leicester
2020-12-10 – 2027-12-31 · Immunoglobulin A Nephropathy, Kidney Diseases, Glomerulonephritis, IGA, Glomerulonephritis, Autoimmune Diseases, Immune System Diseases
What this study did
NCT05856760 · Travere Therapeutics, Inc.
2023-05-19 – 2024-10-25 · Immunoglobulin A Nephropathy
What this study did
Other / comorbidity
NCT05630612 · University of Edinburgh
2022-12-08 – 2027-09-01 · ANCA Associated Vasculitis, Cardiovascular Diseases, Kidney Diseases
What this study did
Phase 1 (2)
Other / comorbidity
NCT07224776 · Brigham and Women's Hospital
2026-07-10 – 2028-12-01 · Proteinuric Renal Disease, Proteinuric Kidney Disease, Proteinuria, Proteinuria in Nephrotic Range
What this study did
NCT05562362 · Travere Therapeutics, Inc.
2020-06-18 – 2020-11-12 · Healthy Subjects
What this study did
Phase 4 (1)
Focal Segmental Glomerulosclerosis
NCT07219121 · Travere Therapeutics, Inc.
2025-10-07 – 2027-05 · Proteinuria, Immunoglobulin A (IgA) Nephropathy, Focal Segmental Glomerulosclerosis, Kidney Transplant
What this study did

Competitive landscape

Other Angiotensin II receptor type 1 (AT1R) + Endothelin receptor type A (ETA) drugs

HS-10390. Compare all 2 Angiotensin II receptor type 1 (AT1R) + Endothelin receptor type A (ETA) drugs

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Focal Segmental Glomerulosclerosis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Sparsentan (Filspari): this drugApprovedSmall moleculeAngiotensin II receptor type 1 (AT1R) + Endothelin receptor type A (ETA)Partial signalNo reviewed efficacy summary in this indication
ApecotrepPhase 3Small moleculeTRPC6 (transient receptor potential cation channel subfamily C member 6)not yet gradedNo reviewed efficacy summary in this indication
HS-10390
Phase 2(overall)
Small moleculeAngiotensin II receptor type 1 (AT1R) + Endothelin receptor type A (ETA)
not yet graded(overall)
No reviewed efficacy summary in this indication
PraliciguatPhase 2Small moleculeSoluble guanylate cyclasenot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Filspari (sparsentan) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 1Proteinuric Renal Disease, Proteinuric Kidney Disease, Proteinuria, Proteinuria in Nephrotic RangeRecruiting
Est. primary completion 2026-12-01 · NCT07224776 · CT.gov ↗
What to watch
2027 (3)
March 2027 (2)
Phase 4IgA NephropathyActive not recruiting
Est. primary completion 2027-03 · NCT07219121 · CT.gov ↗
What to watch
Phase 2IgA NephropathyRecruiting
Est. primary completion 2027-03-12 · NCT05003986 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2IgA NephropathyRecruiting
Est. primary completion 2027-12-31 · NCT04663204 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

14 April 2026ApprovalFDA approves FILSPARI for FSGS
US, FDA · Source ↗
5 September 2024ApprovalFDA grants full approval of Filspari in IgA nephropathy
US, FDA · Source ↗